Literature DB >> 16670298

Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1.

Heather Jackson1, Nektaria Dimopoulos, Nicole A Mifsud, Tsin Yee Tai, Qiyuan Chen, Suzanne Svobodova, Judy Browning, Immanuel Luescher, Lisa Stockert, Lloyd J Old, Ian D Davis, Jonathan Cebon, Weisan Chen.   

Abstract

Immunodominance has been well-demonstrated in many antiviral and antibacterial systems, but much less so in the setting of immune responses against cancer. Tumor Ag-specific CD8+ T cells keep cancer cells in check via immunosurveillance and shape tumor development through immunoediting. Because most tumor Ags are self Ags, the breadth and depth of antitumor immune responses have not been well-appreciated. To design and develop antitumor vaccines, it is important to understand the immunodominance hierarchy and its underlying mechanisms, and to identify the most immunodominant tumor Ag-specific T cells. We have comprehensively analyzed spontaneous cellular immune responses of one individual and show that multiple tumor Ags are targeted by the patient's immune system, especially the "cancer-testis" tumor Ag NY-ESO-1. The pattern of anti-NY-ESO-1 T cell responses in this patient closely resembles the classical broad yet hierarchical antiviral immunity and was confirmed in a second subject.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16670298     DOI: 10.4049/jimmunol.176.10.5908

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Hitting the Target: How T Cells Detect and Eliminate Tumors.

Authors:  Anthony E Zamora; Jeremy Chase Crawford; Paul G Thomas
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Cancer Vaccines 2007. Cancer and HIV Vaccines: Shared Lessons. October 4-6, 2007, New York, USA. Abstracts.

Authors: 
Journal:  Cancer Immun       Date:  2008

3.  In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.

Authors:  Julien Schmidt; Philippe Guillaume; Danijel Dojcinovic; Julia Karbach; George Coukos; Immanuel Luescher
Journal:  J Biol Chem       Date:  2017-05-23       Impact factor: 5.157

4.  Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.

Authors:  Pavol Kudela; Zhaojun Sun; Julien Fourcade; Bratislav Janjic; John M Kirkwood; Bernard Maillere; Hassane M Zarour
Journal:  J Immunol       Date:  2010-12-03       Impact factor: 5.422

5.  A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.

Authors:  Rona Y Zhao; Nicole A Mifsud; Kun Xiao; Kok-Fei Chan; Sara Oveissi; Heather M Jackson; Nektaria Dimopoulos; Philippe Guillaume; Ashley J Knights; Tamara Lowen; Neil C Robson; Sarah E Russell; Emmanuel Scotet; Ian D Davis; Eugene Maraskovsky; Jonathan Cebon; Immanuel F Luescher; Weisan Chen
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

6.  Identification of Two Lpp20 CD4+ T Cell Epitopes in Helicobacter pylori-Infected Subjects.

Authors:  Yunshan Ning; Jianbin Ye; Junjie Wen; Danlin Wu; Zhongbiao Chen; Yanqing Lin; Bingxin Hu; Meiqun Luo; Jun Luo; Lijun Ning; Yan Li
Journal:  Front Microbiol       Date:  2018-05-23       Impact factor: 5.640

7.  Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.

Authors:  Jonathan S Cebon; Martin Gore; John F Thompson; Ian D Davis; Grant A McArthur; Euan Walpole; Mark Smithers; Vincenzo Cerundolo; P Rod Dunbar; Duncan MacGregor; Cyril Fisher; Michael Millward; Paul Nathan; Michael P N Findlay; Peter Hersey; T R Jeffry Evans; Christian Hermann Ottensmeier; Jeremy Marsden; Angus G Dalgleish; Pippa G Corrie; Marples Maria; Margaret Brimble; Geoff Williams; Sintia Winkler; Heather M Jackson; Liliana Endo-Munoz; Candani S A Tutuka; Ralph Venhaus; Lloyd J Old; Dennis Haack; Eugene Maraskovsky; Andreas Behren; Weisan Chen
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

8.  PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses.

Authors:  Yusuf Dölen; Uzi Gileadi; Ji-Li Chen; Michael Valente; Jeroen H A Creemers; Eric A W Van Dinther; N Koen van Riessen; Eliezer Jäger; Martin Hruby; Vincenzo Cerundolo; Mustafa Diken; Carl G Figdor; I Jolanda M de Vries
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

9.  Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.

Authors:  Katherine Woods; Ashley J Knights; Matthew Anaka; Ralf B Schittenhelm; Anthony W Purcell; Andreas Behren; Jonathan Cebon
Journal:  J Immunother Cancer       Date:  2016-02-16       Impact factor: 13.751

10.  Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.

Authors:  Michael T Bethune; Xiao-Hua Li; Jiaji Yu; Jami McLaughlin; Donghui Cheng; Colleen Mathis; Blanca Homet Moreno; Katherine Woods; Ashley J Knights; Angel Garcia-Diaz; Stephanie Wong; Siwen Hu-Lieskovan; Cristina Puig-Saus; Jonathan Cebon; Antoni Ribas; Lili Yang; Owen N Witte; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-22       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.